CTLA4 and melanoma: A study of PBMCs from patients with castration resistant prostate cancer and melanoma treated with ipilimumab or tremelimumab suggested that CTLA-4 blockade leads to T-cell repertoire evolution and diversification—and that improved clinical outcomes were associated with preservation of clonotype diversity [58].